Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

    ... physician. Disease status: AML in ≥ 1st remission - excluding those in 1st remission with 'good risk' cytogenetic features (i.e. t(8;21), t(15;17), inv 16). Secondary AML ...

    Clinical Trial last updated 04/29/2016 - 12:40pm.

  2. Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

    ... One of the following: a. Acute leukemia past first remission, in first or subsequent relapse, in second or greater remission. ... in first remission should have with intermediate or high cytogenetic risk factors or flt3 mutation . Patients with relapsed ...

    Clinical Trial last updated 06/06/2016 - 12:41pm.

  3. UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

    ... typically short lived. Acute Leukemias: Must be in remission by morphology (<5% blasts ). Note cytogenetic relapse or persistent disease without morphologic relapse is ...

    Clinical Trial last updated 04/29/2016 - 10:06am.

  4. Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

    ... Acute myelogenous leukemia (AML): Complete first remission (CR1) at high risk for relapse as defined by: Known prior ... and >100,000 for Tcell lineage; Presence of a high-risk cytogenetic abnormality such as t(9;22), t(1;19), t(4;11) or other MLL ...

    Clinical Trial last updated 04/29/2016 - 3:51pm.

  5. Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

    ... AML defined as: Age > 60, or Presence of complex cytogenetic abnormalities (with > 3 cytogenetic abnormalities), del (7q, -5, ... within 14 days prior to administration of 1st dose of remission induction chemotherapy ; if a bone marrow aspirate and biopsy ...

    Clinical Trial last updated 06/13/2016 - 3:31pm.

  6. Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

    ... Acute Lymphoblastic Leukemia (ALL) in first complete remission (CR1) that is NOT considered favorable-risk. Acute ... unique morphologic markers (e.g. Auer rods) or associated cytogenetic markers that allows morphologic relapse to be distinguished are not ...

    Clinical Trial last updated 06/06/2016 - 10:54am.

  7. Acute Myeloid Leukemia (AML)

    ... under a microscope and how many blast cells are present. Cytogenetic testing and molecular genetic testing that looks at abnormalities ... progresses fast. The initial goal is to put the patient into remission. The long-term goal is to cure the disease, although this is not ...

    Topic section last updated 07/07/2016 - 3:15pm.

  8. Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

    ... Leukemias: Acute myeloid leukemia: high risk complete remission 1 (CR1) (as evidenced by preceding myelodysplastic syndrome (MDS), ... unique morphologic markers (e.g. Auer rods) or associated cytogenetic markers that allows morphologic relapse to be distinguished are not ...

    Clinical Trial last updated 05/02/2016 - 2:13pm.

  9. FAQs

    ... ( blasts ) in your bone marrow. 4. The number of cytogenetic changes you have in bone marrow cells (abnormal gene changes ... of disease characteristics and symptoms after a period of remission. What is a remission? A remission is a partial or ...

    Topic section last updated 03/02/2016 - 11:42am.

  10. Nonmyeloablative Haploidentical Transplant Followed by MLN9708

    ... Acute Myelogenous Leukemia (2nd or subsequent complete remission [CR] (OR) Primary induction chemotherapy failure, but subsequently ... therapy Multiple Myeloma (Presence of a poor risk cytogenetic abnormality [i.e. 17p, t(4;14)], Relapse post autologous ...

    Clinical Trial last updated 04/29/2016 - 1:05pm.